Metraipolis › archive › dc_2cdfca60692b

NDV-GT wth hyperacute rejection in cancer therapy — Europe PMC PMID:41616936

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41616936
DOI: 10.1016/j.virusres.2026.199693
License (as archived): solo-consultazione
Archived: 2026-11-06T11:48:46.360Z
SHA-256 of the archived text: 06eb79afac19c4106377f4e3ef62f95d1c77378fb752d4866fe642948e4eda52
Stable URL of this page: https://metraipolis.com/documento/dc_2cdfca60692b

How to cite

NDV-GT wth hyperacute rejection in cancer therapy — Europe PMC PMID:41616936 — Europe PMC (en), https://europepmc.org/article/MED/41616936 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2cdfca60692b (Metraipolis archive dc_2cdfca60692b, sha256 06eb79afac19c4106377f4e3ef62f95d1c77378fb752d4866fe642948e4eda52)

BibTeX

@misc{dc2cdfca60692b,
  title = {NDV-GT wth hyperacute rejection in cancer therapy — Europe PMC PMID:41616936},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41616936},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2cdfca60692b; sha256 06eb79afac19c4106377f4e3ef62f95d1c77378fb752d4866fe642948e4eda52},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41616936. Agents can read the archived copy with the MCP tool read_document.